AP
APVO.US Aptevo Therapeutics Inc
- Market cap
- USD 2.91M
- P/E
- 0.0x
- P/B
- 0.23x
- ROE
- -432.1%
- Dividend yield
- 54.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is APVO.US undervalued?
Graham numberThe Graham number of Aptevo Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aptevo Therapeutics Inc fundamental analysis
No fundamental analysis for Aptevo Therapeutics Inc yet.
Aptevo Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipleta…
Full company profileAptevo Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aptevo Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 36.4M | 14.7M | 23.1M | 32.4M | 4.31M | 12.3M | 3.11M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.3M | 9.65M | 11.9M | -2.24M | -13.5M | 12.3M | 3.11M | -567K | -352K | -240K | - |
| Operating Income | -127M | -53.9M | -51.7M | -41.0M | -27.5M | -21.4M | -28.6M | -28.9M | -24.6M | -26.3M | -26.6M |
| EBITDA | -64.4M | -48.9M | -49.3M | -40.8M | -26.2M | -20.3M | 7.92M | -18.1M | -23.8M | -25.7M | -26.3M |
| Net Income | -112M | 6.97M | -53.7M | -44.7M | -17.8M | -27.3M | 8.03M | -17.4M | -24.1M | -26.0M | -26.1M |
| EPS | -3,421 | 201 | -1,087,703 | -6,984,063 | -3,065,630 | -3,414,125 | 921,584 | -829,095 | -31,460 | -8,230 | -22 |
| Balance Sheet | |||||||||||
| Total Assets | 91.9M | 117M | 67.5M | 53.4M | 53.5M | 56.6M | 34.2M | 24.8M | 15.6M | 27.2M | 14.5M |
| Total Liabilities | 41.3M | 35.0M | 37.1M | 41.6M | 37.0M | 55.4M | 16.2M | 12.6M | 10.8M | 9.81M | 8.48M |
| Shareholders' Equity | 50.6M | 82.0M | 30.4M | 11.8M | 16.6M | 1.22M | 18.0M | 12.2M | 4.76M | 17.4M | 6.04M |
| Cash & Short-term Investments | 54.5M | 80.8M | 30.6M | 12.4M | 40.0M | 45.0M | 22.6M | 16.9M | 8.71M | 21.6M | 9.80M |
| Total Debt | 18.4M | 19.1M | 19.3M | 23.2M | 27.4M | 16.7M | 9.54M | 5.40M | 4.63M | 4.63M | 4.21M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -36.9M | -41.6M | -51.4M | -42.4M | -29.3M | -21.7M | -21.0M | -11.7M | -23.8M | -25.6M | -26.8M |
| Capital Expenditure | 2.51M | 1.40M | 976K | 153K | 88.0K | 713K | 29.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -39.4M | -43.0M | -52.4M | -42.5M | -29.4M | -22.4M | -21.1M | -11.7M | -23.8M | -25.6M | -26.8M |
| Ratios | |||||||||||
| ROE | -222.3% | 8.5% | -176.6% | -377.5% | -107.0% | -2,246.1% | 44.7% | -142.5% | -507.5% | -149.4% | -432.1% |
| ROA | -122.4% | 6.0% | -79.5% | -83.7% | -33.1% | -48.3% | 23.5% | -70.1% | -154.8% | -95.5% | -179.8% |
| Net Profit Margin | -308.5% | 47.6% | -232.8% | -137.9% | -411.9% | -222.2% | 257.8% | - | - | - | - |
| Debt to Equity | 0.36x | 0.23x | 0.63x | 1.96x | 1.65x | 13.75x | 0.53x | 0.44x | 0.97x | 0.27x | 0.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aptevo Therapeutics Inc dividends
- Dividend yield
- 54.06%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.57M | 498 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 4.00K | 459 | 0.0% |
| 2021 | USD 10.2M | 1,279,125 | - |
| 2020 | USD 21.2M | 3,669,603 | - |
| 2019 | USD 58.0K | 9,063 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:18 on Dec 30, 2025.
Who owns Aptevo Therapeutics Inc
- Insiders 4.15%
- Institutions 17.35%
- Public & others 78.50%
- Shares outstanding 4.89M
- Free float 1.73M
Top funds holding APVO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 6.35K | 0.30% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.55K | 0.07% | 0.00% | Sep 2026 |
Top institutions holding APVO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GSA Capital Partners LLP | 21.5K | 1.19% | +9.68% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.7K | 0.70% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 10.8K | 0.60% | -18.86% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 4.14K | 0.23% | 0.00% | Jun 2026 |
| UBS Group AG | 730.00 | 0.04% | -78.81% | Jun 2026 |
| Advisor Group Holdings, Inc. | 360.00 | 0.02% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 109.00 | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 31.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
Aptevo Therapeutics Inc company profile
- Company name
- Aptevo Therapeutics Inc
- Ticker
- APVO.US
- Exchange
- USA Stocks
- Listed since
- Jul 20, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 2401 4th Avenue, Seattle, WA, United States, 98121
- Phone
- 206 838 0500
- Website
- aptevotherapeutics.com
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics Inc management
7- Mr. Marvin L. WhiteExecutive Chair · born 1962
- Mr. Jeffrey G. Lamothe CACEO, President & Director · born 1966
- Ms. SoYoung Kwon J.D., LL.M.Corporate Secretary, Senior VP, General Counsel, Business Development & Corporate Affairs · born 1969
- Ms. Daphne L. Taylor CPASenior VP & CFO · born 1966
- Ms. Mary J. Janatpour Ph.D.Senior VP & Chief Scientific Officer · born 1967
- Ms. Miriam Weber MillerVice President of Investor Relations & Corporate Communications
- Dr. Dirk Huebner M.D.Senior Vice President & Chief Medical Officer · born 1963